Tanovea® para o tratamento de linfoma em cães

Autores

Erik De Clercq

Abstract

Tanovea® (first named GS-9219, then VDC-1101, generic name: rabacfosadine) is a pro-prodrug or “double”
prodrug of PMEG [9-(2-phosphonylmethoxyethyl)guanine], which has been conditionally approved by the US
FDA (Food and Drug Administration) for the treatment of lymphoma in dogs. Tanovea has been demonstrated to
be effective against non-Hodgkin’s lymphoma (NHL) in dogs, as well as canine cutaneous T-cell lymphoma,
spontaneous canine multiple myeloma, naïve canine multicentric lymphoma and relapsed canine B-cell lymphoma. As a double prodrug of PMEG, GS-9219 is first converted intracellularly by hydrolysis to cPr-PMEDAP,
then deaminated to PMEG, which is then phosphorylated twice to its active metabolite PMEGpp, acting at the
level of the cellular DNA polymerases.

Keywords

Tanovea, PMEG, cPr-PMEDAP, Lymphoma, Dogs